

Index

A

- ADAM9, 213
- ADAM10, 215
- ADAM17
 - breast remodeling role, 213, 215–216
 - epidermal growth factor receptor substrates, 91
 - knockout mouse, 77
- Akt, phosphatidylinositol 3-kinase signaling, 146–147
- ALD1. *See* Aldehyde dehydrogenase
- Aldehyde dehydrogenase (ALD1), mammosphere enrichment, 63
- Androgen receptor (AR), breast development role, 91
- Apoptosis, multiphoton microscopy studies, 309
- AR. *See* Androgen receptor

B

- Basement membrane. *See* Extracellular matrix
- B cell, breast cancer role, 240–241
- β -Lactoglobulin (BLG), promoter for transgenic mice, 26
- Bioluminescence imaging (BLI), breast cancer imaging, 300
- Bissel, Mina, 132
- Bittner, John J., 17
- BLG. *See* β -Lactoglobulin
- BLI. *See* Bioluminescence imaging
- BMPs. *See* Bone morphogenetic proteins
- Bone morphogenetic proteins (BMPs), ductal branching morphogenesis role, 185–186
- BRCA1*
 - knockout mouse, 34–35
 - mutations in breast cancer, 152–153
 - protein–protein interactions, 153
 - transgenic mouse models of breast cancer, 154–155
- BRCA2*
 - knockout mouse, 35, 153–154
 - mutations in breast cancer, 153
 - transgenic mouse models of breast cancer, 155
- Breast cancer. *See also* Historical perspective, mouse mammary cancer research; Invasion; Metastasis
 - BRCA transgenic mouse models
 - BRCA1, 154–155
 - BRCA2, 155
 - breast development relevance, 187–188
 - cytokine signaling, 98–100

- DNA methylation studies
 - hypermethylated genes, 282
 - hypomethylated genes, 282–284
 - transformed breast epithelial cells, 280–282
- extracellular matrix
 - breakdown
 - basement membrane crossing, 114–115
 - in situ carcinoma, 114
 - metastasis, 115–116
 - stromal invasion, 115
 - density and alignment in tumor progression, 135–137
 - estrogen extracellular matrix assembly control and cancer implications, 135
 - therapeutic targeting, 116
- functional genetics studies
 - chemotherapy studies, 271–272
 - gain-of-function screens, 268–269
 - loss-of-function screens, 265–268
 - phenotype defining, 270–272
 - prospects for study, 274
 - therapeutic targets
 - pathway gene identification, 269–270
 - synthetic lethal interactions, 272–274
- genomic alterations associated with intrinsic subtypes
 - clinical utility, 255–256
 - metastasis, 256–258
 - overview, 254–255
- histone modification, 286–287
- human breast stem cell hierarchy in origin
 - prediction, 66
- imaging
 - macroscopic imaging techniques, 294–300
 - microscopic imaging techniques
 - apoptosis and therapeutic response studies, 309
 - fate mapping of tumor cells, 308–309
 - intraoperative imaging, 309–310
 - invasion and metastasis studies, 305–308
 - mammary models, 300–301
 - mitosis studies, 309
 - multiphoton microscope design and software, 301–304
 - types, 300
 - overview, 293–294
 - reporters and labels, 304–305

Index

Breast cancer (*Continued*)

- immune cells in development, 234–241
- inflammation role in progression, 170, 172–173
- microenvironment. *See* Microenvironment
- oncogenes. *See specific genes*
- phosphatidylinositol 3-kinase signaling, 146–147
- stroma importance, 254
- transforming growth factor- β studies, 198–200
- tumor suppressor genes. *See specific genes*
- types
 - basal-like subtype, 252–253
 - claudin-low subtype, 253–254
 - discovery of intrinsic subtypes, 247–250
 - HER2-enriched subtype, 251–252
 - luminal subtypes, 250–251
 - mouse models, 27–28

Breast development

- breast cancer relevance, 187–188
- bud maturation, 183–185
- cytokine signaling, 96–98
- duct branching morphogenesis, 185–187
- dynamic stages, 206–208
- extracellular matrix
 - cell–matrix interactions
 - branching ductal morphogenesis, 108–110
 - ductal patterning, 111–113
 - polarized mammary duct formation, 110–111
 - developmental changes
 - fibronectin regulation of mechanical properties, 133–135
 - overview, 132–133
- hormonal control in mouse
 - differential hormone action mechanisms, 78
 - estrogen, 73–74
 - growth hormone, 74
 - overview, 72
 - progesterone, 74–75
 - prolactin, 74–75
 - signaling, 76–78
 - systemic versus local effects, 72–73
- human, 56–58
- microenvironment role, 164–166
- morphogenesis in embryos, 177–180
- placode development, 183
- prospects for study, 188
- puberty, 226–231
- specification of mammary line, 180–183

C

- CAF. *See* Carcinoma-associated fibroblast
- Carcinogens, history of studies in mice, 4–5
- Carcinoma-associated fibroblast (CAF), extracellular matrix changes, 136–137
- Cardiff, Robert, 29

- CDK10, breast cancer studies, 272
- CDKN2A, hypermethylation in breast cancer, 282
- Chromatin remodeling. *See* DNA methylation; Histone modification
- Collagen. *See* Extracellular matrix
- Colony-stimulating factor-1 (CSF-1)
 - breast cancer role, 236
 - knockout mouse, 229–230
 - lactation role, 232
 - pubertal mammary development role, 226, 229
- COX. *See* Cyclooxygenase
- CpG island. *See* DNA methylation
- CSF-1. *See* Colony-stimulating factor-1
- Cyclooxygenase (COX), inhibitor effects on tumor progression, 170, 172
- Cytokine signaling. *See* JAK/Stat signaling

D

- DCIS. *See* Ductal carcinoma in situ
- Development. *See* Breast development
- DNA methylation
 - abundance in human genome, 278–280
 - analytical techniques, 279
 - breast cancer studies
 - hypermethylated genes, 282
 - hypomethylated genes, 282–284
 - transformed breast epithelial cells, 280–282
 - histone modification relationship in gene silencing, 287–288
 - methyltransferases, 278
 - prospects for study, 288
 - transforming growth factor- β regulation, 200
- Ductal branching. *See* Breast development
- Ductal carcinoma in situ (DCIS)
 - microenvironment abnormalities, 169
 - mammary intraepithelial neoplasia outgrowth model, 32–33, 37
- Dunn, Thelma, 16
- Dvorak, Harol, 171

E

- E-cadherin, knockout mouse, 35–36
- ECM. *See* Extracellular matrix
- EGFR. *See* Epidermal growth factor receptor
- EMT. *See* Epithelial-to-mesenchymal transition
- Eosinophil, pubertal mammary development role, 227–228, 230
- Epidermal growth factor receptor (EGFR). *See also Erbb2*
 - breast development role, 90–92, 212
 - ErbB family, 88
 - knockout mouse, 77

- macrophage delivery of ligands in breast cancer, 237
- mammary cancer development role, 93
- Epigenetics. *See* DNA methylation; Histone modification
- Epithelial cell
 - cell–cell interactions, 210
 - stem cells. *See* Human breast stem cells; Murine mammary stem cell
 - types in mammary gland, 208–209
- Epithelial-to-mesenchymal transition (EMT)
 - breast development, 187
 - breast epithelium, 64
 - history of study, 16, 20
 - interleukin-6 induction, 99
- ErbB2*
 - signaling effects on cell cycle progression and transcription factor networks, 151
 - transgenic mouse models, 30–31, 93, 147–149
- Estrogen
 - extracellular matrix assembly control and cancer implications, 135
 - receptor
 - coregulators, 79–82
 - knockout mice
 - ER α , 73–74
 - ER β , 74
 - signaling, 76–77
 - structure, 78–79
 - regulation of release, 72–73
 - transforming growth factor- β regulation, 197
- Ets2, PTEN effects, 171
- Extracellular matrix (ECM)
 - cell force
 - contractile pathways in generation, 128–129
 - measurement, 127–128
 - cell–matrix interactions
 - breakdown in breast cancer
 - basement membrane crossing, 114–115
 - in situ carcinoma, 114
 - metastasis, 115–116
 - stromal invasion, 115
 - breast development role
 - branching ductal morphogenesis, 108–110
 - ductal patterning, 111–113
 - polarized mammary duct formation, 110–111
 - mammary differentiation role
 - integrin-prolactin cross talk, 113–114
 - involution, 114
 - overview, 105–108
 - therapeutic targeting in cancer, 116
 - density and alignment in tumor progression, 135–137
 - hormonal control of assembly and cancer implications, 135
 - mechanical properties
 - developmental changes
 - fibronectin regulation of mechanical properties, 133–135
 - overview, 132–133
 - focal complexes as mechanical sensors, 129–131
 - mechanical signaling regulation of proliferation and differentiation, 131–132
 - stiffness, 126–127
 - tensile force dynamics in mammary gland, 126
 - transforming growth factor- β regulation, 124–125
 - tumor invasion and mechanosignaling, 137–138
 - receptors on cells, 124
 - stromal modifiers, 212–214
 - synchronizing parenchymal, stromal, and extracellular matrix homeostasis, 218
 - transforming growth factor- β response, 196

F

- FAK. *See* Focal adhesion kinase
- FGFs. *See* Fibroblast growth factors
- Fibroblast growth factors (FGFs)
 - breast development role, 77, 90–91, 212
 - receptors
 - mammary cancer development role, 92–94
 - types and ligands, 88–89
 - specification of mammary line, 180–182
- Fibronectin (FN), regulation of extracellular matrix
 - mechanical properties, 133–135
- Filamin, mechanical sensor, 11
- Fluorescence molecular tomography (FMT), breast cancer imaging, 296, 300, 304
- FMT. *See* Fluorescence molecular tomography
- FN. *See* Fibronectin
- Focal adhesion kinase (FAK)
 - cell contraction regulation, 129
 - mechanical sensor, 131
 - tumor invasion role, 137
- FSP1, stromal fibroblast function, 171

G

- Gain-of-function screens, breast cancer, 268–269
- GATA-3
 - breast development role, 96–97, 212
 - mammary stem cell regulation in mouse, 50
- GH. *See* Growth hormone
- Growth hormone (GH)
 - breast development role, 91, 211
 - receptor knockout mouse, 74
 - regulation of release, 72–73

Index

H

- Halberg, Franz, 17
- HAN. *See* Hyperplastic alveolar nodule
- Hedgehog, mammary stem cell signaling in mouse, 50
- HIM xenograft. *See* Human in mouse (HIM) xenograft
- Histology, mammary gland, 208–210
- Histone modification
 - breast cancer versus normal epithelial differentiation, 286–287
 - combinatorial variations associated with gene transcription, 284–286
 - DNA methylation relationship in gene silencing, 287–288
 - prospects for study, 288
- Historical perspective, mouse mammary cancer research
 - carcinogen studies, 4–5
 - early years, 1–2, 14–16
 - first description, 14–15
 - genetic studies, 4
 - hormone studies, 2–3
 - human significance, 9–10, 20–21
 - inbred mouse studies, 17
 - mammary stem cells, 18–19, 41–42
 - mouse mammary tumor virus studies, 3–5, 8, 13–14, 17–18
 - pathobiology of tumorigenesis, 5–7
 - timeline, 15
 - transplantation studies, 7–9, 18–19
- Human breast stem cell
 - breast development, 56–58
 - cell line studies, 60–62
 - chemotherapy effects on cancer stem cells, 155–156
 - cytokeratin staining patterns in normal and neoplastic breast tissue, 59–60
 - epithelial stem cell
 - identification, 62–63
 - profiling, 64–66
 - hierarchy in breast cancer origin prediction, 66
 - histone modification, 286
 - mammary remodeling role, 214–215
 - mammosphere culture, 63–64
 - metastasis genomics studies, 259
 - primary culture studies, 58–59
- Human in mouse (HIM) xenograft, history of study, 8–9
- Hyperplastic alveolar nodule (HAN), history of study, 6–7

I

- IGFs. *See* Insulin-like growth factors
- IKBKE*, breast cancer studies, 268
- IL-6. *See* Interleukin-6
- ILC. *See* Invasive lobular carcinoma
- Inbred mouse strains, origins, 14, 16

- Inflammation, tumor progression role, 170, 172–173
- Insulin, receptor, 90
- Insulin-like growth factors (IGFs)
 - binding proteins, 90, 94, 270
 - breast development role
 - IGF-1, 90–91, 211
 - IGF-2, 78
 - mammary cancer development role, 93–94
 - receptors, 89–90
- Integrins
 - oncogene cross talk in mammary tumor progression, 150–151
 - prolactin cross talk in mammary differentiation, 113–114
- Interleukin-6 (IL-6), breast cancer role, 98
- Invasion
 - cell–matrix interactions, 115
 - extracellular matrix mechanosignaling, 137–138
 - multiphoton microscopy studies, 305–306
- Invasive lobular carcinoma (ILC), E-cadherin knockout mouse, 35–36
- Involution
 - cell–matrix interactions, 114
 - immune cell function, 214, 232–234
 - mechanisms, 208

J

- JAK/Stat signaling
 - cytokine receptor families, 95–96
 - mammary cancer development role, 95, 98–100
- Stats
 - breast cancer role, 98–100
 - breast development role, 96–98
 - types, 96

K

- Keratin-5, staining patterns in normal and neoplastic breast tissue, 59–60
- Keratin-14
 - promoter for transgenic mice, 29
 - staining
 - breast development, 56–57
 - patterns in normal and neoplastic breast tissue, 59
- Keratin-19, staining
 - breast development, 56–57
 - patterns in normal and neoplastic breast tissue, 59–61
- Kinesins, breast cancer expression studies, 269
- Knockout mouse
 - ADAM17, 77
 - BRCA1*, 34–35
 - BRCA2*, 35, 153–154

- colony-stimulating factor-1, 229–230
- E-cadherin, 35–36
- epidermal growth factor receptor, 77
- estrogen receptor
 - ER α , 73–74
 - ER β , 74
- growth hormone receptor, 74
- Lef1, 183
- leptin, 76
- Lrp6, 186
- Msx2, 187
- overview of tumor suppressor gene knockout, 29–30, 33
- progesterone receptor, 74
- prolactin receptor, 74
- PTEN, 147
- TP53, 33–34
- transforming growth factor- β , 170, 198
- K-Ras, synthetic lethality targeting of mutants, 273–274
- Kuperwasser, Charlotte, 167

- L**
- Lactation. *See also* Prolactin
 - leukocyte function, 231–232
 - progesterone role, 207–208
- Lathrop, Abbie, 16
- LCIS. *See* Lobular carcinoma in situ
- Lef1
 - knockout mouse, 183
 - mammary bud development role, 184
 - placode development role, 183
- Leptin, knockout effects on breast development, 76
- Little, Clarence Cook, 1, 16–17
- Lobular carcinoma in situ (LCIS), 36
- Loss-of-function screens, breast cancer, 265–268
- Lrp6, ductal branching morphogenesis role, 185
- Lyden, David, 167

- M**
- Macrophage
 - breast cancer role, 236–237
 - involution role, 233
 - lactation role, 232
 - mammary remodeling role, 214
 - pubertal mammary development, 226–228
- Magnetic resonance imaging (MRI), breast cancer imaging, 294, 296, 304–305
- Mammary bud, maturation, 183–185
- Mammary Imaging Window (MIW), 301–302
- Mammary intraepithelial neoplasia outgrowth (MINO) model, 32–33, 37
- Mammosphere culture, human breast stem cells, 63–64

- Mast cell
 - lactation role, 232
 - pubertal mammary development role, 230
- Matrix metalloproteinases (MMPs)
 - mammary remodeling role, 213–214
 - master signals, 216–218
 - paracrine signaling, 215–216
 - synchronizing parenchymal, stromal, and extracellular matrix homeostasis, 218
 - tissue inhibitors, 213
 - tumor microenvironment facilitation, 218–219
 - types and sources in mammary gland, 213
- MDM2
 - inhibitors, 272
 - p53 interactions, 151–152
- Metastasis
 - cell–matrix interactions, 115–116
 - genomic alterations associated with intrinsic breast cancer subtypes, 256–258
 - mouse mammary tumors, 20
 - multiphoton microscopy, 305–308
- Methylation-specific digital karyotyping (MSDK), 279
- Microenvironment
 - breast development role, 164–166
 - matrix metalloproteinases and tumor microenvironment facilitation, 218–219
 - nonmammary stem progenitor cell regulation, 49
 - prospects for study, 173
 - tumor abnormalities
 - clinical relevance in tumorigenesis, 171–173
 - functional relevance in tumorigenesis, 169–170
 - metastasis, 166–169
 - tumor mouse models, 36, 170–171
- MINO model. *See* Mammary intraepithelial neoplasia outgrowth (MINO) model
- MIW. *See* Mammary Imaging Window
- MLC. *See* Myosin light chain
- MMPs. *See* Matrix metalloproteinases
- MMTV. *See* Mouse mammary tumor virus
- Mouse mammary tumor virus (MMTV)
 - carcinogen interactions, 5
 - history of study, 3–5, 8, 13–14, 17–18
 - insertion sites, 18
 - promoter for transgenic mice, 26, 29, 31, 147–149
- MPM. *See* Multiphoton microscopy
- MRI. *See* Magnetic resonance imaging
- MSDK. *See* Methylation-specific digital karyotyping
- Msx1, mammary bud development role, 185
- Msx2, mammary bud development role, 185, 187
- Multiphoton microscopy (MPM)
 - advantages, 300
 - breast cancer applications
 - apoptosis and therapeutic response studies, 309
 - correlating tumor cell behavior with gene expression and markers of metastatic risk, 306, 308

Index

- Multiphoton microscopy (MPM) (*Continued*)
 fate mapping of tumor cells, 308–309
 intraoperative imaging, 309–310
 invasion and metastasis, 305–307
 mitosis studies, 309
 microscope design, 301–303
 reporters, 304
 software for 4D imaging, 302–303
 techniques, 300–301
- Murine mammary stem cell
 epithelial cell hierarchy
 hormonal regulation, 47
 overview, 45–47
 parity-identified cells, 47–48
 history of study, 18–19, 41–42
 isolation, 43–45
 mammary remodeling role, 214–215
 markers, 55
 morphological evidence in epithelium, 42–43
 nonmammary stem progenitor cell regulation by
 microenvironment, 49
 prospects for study, 50–51
 regulators, 49–50
 template DNA selective segregation, 48–49
- Myeloid suppressor cells, breast cancer role, 237
- Myosin light chain (MLC), cell contraction, 129
- N**
- Notch, mammary stem cell signaling in mouse, 50
- Nutlin-3, breast cancer studies, 272
- O**
- Oncogenes. *See specific genes*
- P**
- p53
 cell cycle regulation, 151–152
 gene. *See TP53*
 mammary stem cell self-renewal role in mouse, 50
 MDM2 interactions, 151–152
- p130Cas, mechanical sensor, 129–131
- PAK-1, SRC-3 as substrate, 81
- Parathyroid hormone-related protein (PTHrP)
 ductal branching morphogenesis role, 185–186
 mammary bud development role, 184, 211
- PARP. *See Poly(ADP-ribose) polymerase*
- PET. *See Positron emission tomography*
- Phosphatidylinositol 3-kinase (PI3K), signaling in
 cancer, 146–147
- PI3K. *See Phosphatidylinositol 3-kinase*
- Pierce, Barry, 19
- PITX1*, breast cancer studies, 270–271
- Placode, development, 183, 212
- Pollard, Jeff, 171
- Poly(ADP-ribose) polymerase (PARP), inhibitor
 sensitization via BRCA deficiency, 155
- Positron emission tomography (PET), breast cancer
 imaging, 294, 296, 304
- Progesterone
 lactation role, 207–208
 receptor
 coregulators, 79–82
 estrogen induction, 211
 knockout mouse, 74
 signaling, 77–78
 structure, 78–79
 regulation of release, 72–73
- Prolactin
 integrin-prolactin cross talk in mammary
 differentiation, 113–114
 receptor
 knockout mouse, 74
 signaling, 77–78
 regulation of release, 72–73
- PTEN
 Ets2 effects, 171
 knockout mouse, 147
 loss in breast cancer, 64, 66
 phosphatidylinositol 3-kinase antagonism, 146
- PTHrP. *See Parathyroid hormone-related protein*
- R**
- Radiation, history of cancer induction studies, 5
- RANKL, signaling in breast development, 77–78
- RB. *See Retinoblastoma protein*
- Remodeling, mammary gland. *See also Matrix metalloproteinases*
 epithelial morphogens and inhibitors, 211–212
 immune cells, 214
 master signals, 216–218
 paracrine signaling, 215–216
 stem cells, 214–215
 stromal extracellular matrix modifiers, 212–214
 synchronizing parenchymal, stromal, and
 extracellular matrix homeostasis, 218
 systemic mammogens, 210–211
- REST*, breast cancer studies, 271
- Retinoblastoma protein (RB), cell cycle regulation, 151
- Rho
 cell contraction regulation, 129
 mammary bud development role, 184
- RNA interference, screens in breast cancer, 265–270
- ROCK, cell contraction regulation, 129
- S**
- SDPP. *See Stroma-derived prognostic predictor*
- Sgroi, Dennis, 168

ShcA, signaling in tumor progression, 150
Single Sample Predictor (SSP), 248
SMADs, transforming growth factor- β signaling, 192–194
Snell, George, 17
c-Src, signaling in tumor progression, 150
SRC coactivators
 SRC-3 level and activity regulation, 80–82
 steroid hormone receptor regulation, 80
SSP. *See* Single Sample Predictor
Stat. *See* JAK/Stat signaling
Stem cell. *See* Human breast stem cell; Murine mammary stem cell
Stevens, Roy, 19
Stroma-derived prognostic predictor (SDPP), 172
Synthetic lethality, breast cancer studies, 272–274

T

TACS. *See* Tumor associated collagen signatures
Talin, mechanical sensor, 129–130
Tbx3, deficiency and ulnar-mammary syndrome, 182
T cell, breast cancer role, 238–240
TDLU. *See* Terminal ductal-lobular unit
TEB. *See* Terminal end bud
Terminal ductal-lobular unit (TDLU), 56, 238
Terminal end bud (TEB), development, 77, 90–92, 133, 206, 208–210, 213, 227–231
TGF- β . *See* Transforming growth factor- β
TIMPs. *See* Matrix metalloproteinases
TP53
 knockout mouse, 33–34
 mutations in cancer, 152
Transforming growth factor- β (TGF- β)
 activation, 192
 breast cancer studies, 198–200
 breast development role, 207, 212
 breast remodeling role, 212, 216
 epigenetic regulation, 200
 estrogen regulation, 197
 extracellular matrix response, 196
 human breast stem cell signaling, 66

knockout mouse, 170, 198
mammary distribution, 195–196
prospects for study, 200–201
receptors, 192, 198–199
signaling, 192–194
transgenic mice, 196–197
Transgenic mouse
 BRCA mutant models of breast cancer
 BRCA1, 154–155
 BRCA2, 155
 ErbB2 models, 30–31, 93, 147–149
 mammary-specific promoters, 26, 29
 transforming growth factor- β , 196–197
Transplantation models
 historical perspective, 7–9, 18–19
 human in mouse xenograft, 8–9
 overview, 31–32
Tumor associated collagen signatures (TACS), 136
Tumor suppressor genes. *See specific genes*
TWIST, epithelial-to-mesenchymal transition mediation, 99
Two-photon microscopy. *See* Multiphoton microscopy

V

Vascular endothelial growth factor (VEGF)
 matrix metalloproteinase regulation, 216
 metastasis genomics signature, 258–259
 myeloid cell delivery, 236
VEGF. *See* Vascular endothelial growth factor

W

WAP. *See* Whey acidic protein
Whey acidic protein (WAP), promoter for transgenic mice, 26
Wnt
 mammary bud development role, 184, 186
 mammary stem cell signaling in mouse, 50
 placode development role, 183
 specification of mammary line, 180